Lonza presented its strategic outlook at Morgan Stanley's 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026. Chief financial officer Philippe Deecke highlighted a shift toward a cash‑generating model while maintaining the company's position as a contract development and manufacturing organization (CDMO).
The Swiss‑based firm, valued at $46 billion with a price‑to‑earnings multiple of 34.7, reported 28% year‑to‑date growth in its Advanced Synthesis segment, where EBITDA margins peaked at 48% before normalizing to around 40%. Integrated Biologics is expected to grow roughly 10% in 2026, while the specialized modalities business is moving toward the group's overall margin range of 32%‑34%.
Lonza's organic growth target is set at 10%‑13% annually. To fund this, the company plans to reduce capital expenditures from over 20% of sales to a range of 14%‑19%, aligning with its mid‑to‑high‑teens CapEx target. Deecke said the transition marks the end of a heavy‑investment phase and will support the planned capacity expansions at the Vacaville, California, site and a $6 × 20,000‑liter expansion in Visp, Switzerland. The Vacaville transformation will keep output flat through 2027, with growth resuming in 2028.
Customer retention remains a cornerstone of Lonza's model. Early‑stage compounds captured in Phase I stay with the firm at a 99% rate, according to Deecke, who noted that such compounds typically progress to commercial status. Early‑stage work now accounts for about 10% of sales, and the customer base is evenly split between large pharmaceutical companies and biotech firms.
The company also announced a 60% divestment of its Capsules & Health Ingredients division, slated for completion by the end of 2026. Regarding external factors, Lonza said it sells products at warehouse doors, limiting direct U.S. tariff exposure, and that raw‑material tariffs are passed through to customers. The recently introduced BIOSECURE legislation was said to have no measurable revenue impact.
Looking ahead, Lonza will hold a Capital Markets Day in October 2026 at its Vacaville facility, where it expects to detail execution plans for the next growth phase. The firm also cited the antibody‑drug conjugate market, projected to expand about 20% over the next five years, as a key opportunity.
Overall, Lonza's guidance emphasizes disciplined investment, margin improvement and a balanced portfolio of large‑scale biologics and specialized modalities as it navigates the evolving CDMO landscape.
